welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy
CureDuchenne, a national venture philanthropy nonprofit focused on finding a cure for Duchenne muscular dystrophy (DMD), announced today a $500,000 investment into 4D Molecular Therapeutics (4DMT), a world-leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, in an effort to advance gene therapy.
“Our investment into 4DMT will be the fourth investment by CureDuchenne Ventures, the investment arm of CureDuchenne, into gene therapy and gene editing. So far, we have had preclinical success in this area for Duchenne with our investments in duplication 2 exon skipping at Nationwide Children’s Hospital, Bamboo Therapeutics/Pfizer and Exonics Therapeutics, and we are very positive about the prospect of 4DMT’s work,” said Debra Miller, founder and CEO of CureDuchenne. “CureDuchenne’s investments are moving quickly through the drug development process and we look forward to safety and efficacy data for these potential therapies.”
rareRelated
-
Molecular therapy in a novel translational large animal model for Duchenne muscular dystrophyThe development of efficient and safe st...
-
CHMP opposes approval of Exondys 51 to treat DMD in EuropeThe Committee for Medicinal Products for...
-
Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular DisordersThe hypothesis is that a mechanical insu...
-
Duchenne Pulmonary Awareness: C-PAP/BiPAPhttps://www.youtube.com/watch?v=_EuyErNY...
-
Insurers battle families over costly drug for fatal diseaseNolan and Jack Willis, twins from upstat...
-
Duchenne Muscular Dystrophy Tissue Bank for Exon SkippingWe will utilize the Cooperative Internat...
-
A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of Casimersen, Eteplirsen and Golodirsen in Subject...This is an 48-week open-label study to d...
-
First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy TrialMallinckrodt plc, a leading global spec...
